PTCT

In Q2 2026, PTC Therapeutics reported a significant increase in revenue, jumping 102% year-over-year to $361 million and surpassing analyst estimates by 22%, with product sales more than doubling. Following these strong results, the company raised its full-year 2026 revenue guidance to a range of $1.18 billion to $1.28 billion. The company's Q2 2026 earnings per share of $0.92 significantly beat estimates by 188%. Sephience revenue reached $161 million, a 21% sequential increase, with 1,647 patients globally on therapy. PTC Therapeutics' cash position improved to $2.23 billion at the end of Q2 2026, an increase of $280 million from year-end 2025. In September 2026, PTC Therapeutics acquired ST-920 from Sangamo Therapeutics to expand its rare disease portfolio. On October 7, 2026, director Michael Schmertzler sold 2,500 common shares under a Rule 10b5-1 plan. As of October 6, 2026, the share price was $63.70, representing a slight decline of 0.32% from October 7, 2025.